These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 29127255)
1. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255 [TBL] [Abstract][Full Text] [Related]
2. Development of phospho-specific Rab protein antibodies to monitor Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256 [TBL] [Abstract][Full Text] [Related]
11. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls. Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855 [TBL] [Abstract][Full Text] [Related]
12. Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease. Eyers PA Biochem J; 2018 Jan; 475(1):185-189. PubMed ID: 29305429 [TBL] [Abstract][Full Text] [Related]
13. Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors. Ito G; Katsemonova K; Tonelli F; Lis P; Baptista MA; Shpiro N; Duddy G; Wilson S; Ho PW; Ho SL; Reith AD; Alessi DR Biochem J; 2016 Sep; 473(17):2671-85. PubMed ID: 27474410 [TBL] [Abstract][Full Text] [Related]
15. Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites. Nirujogi RS; Tonelli F; Taylor M; Lis P; Zimprich A; Sammler E; Alessi DR Biochem J; 2021 Jan; 478(2):299-326. PubMed ID: 33367571 [TBL] [Abstract][Full Text] [Related]
16. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor. Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114 [TBL] [Abstract][Full Text] [Related]
17. 'Up with the LRRK': a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement. Eyers PA Biochem J; 2016 Sep; 473(18):2757-62. PubMed ID: 27621483 [TBL] [Abstract][Full Text] [Related]
19. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046 [TBL] [Abstract][Full Text] [Related]